Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2021-11-16 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form (Form 52-109FV1) signed by the CEO certifying the accuracy and fair presentation of the annual financial statements and MD&A for the fiscal year ended July 31, 2021. It explicitly states it is a certification of annual filings for a venture issuer and does not contain the actual financial statements or detailed report content. The document is short (3043 characters) and serves as an officer attestation rather than the full annual report itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the Annual Report (10-K).
2021-11-16 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Management Certification related to Form 13-502F1 for Class 1 and Class 3B Reporting Issuers, submitted to the Ontario Securities Commission. It contains certification by an officer regarding the completeness and accuracy of the information provided in the form, which relates to participation fees and market value calculations. The document does not contain financial statements or substantive financial data typical of an Annual Report or Interim Report. It is primarily a certification letter accompanying a regulatory form submission. Therefore, it fits the criteria for Regulatory Filings (RNS) as it is an officer certification and regulatory submission rather than a full financial report or announcement.
2021-11-16 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Independent Auditor's Report' and contains detailed audit opinions, audit responsibilities, and the consolidated financial statements for Marvel Biosciences Corp. for the years ended July 31, 2021 and 2020. It includes the auditor's opinion on the financial statements, basis for opinion, material uncertainty related to going concern, and detailed financial statements such as the consolidated statements of financial position, loss and comprehensive loss, cash flows, and changes in shareholders' equity. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an Audit Report / Information filing, which includes standalone audit reports and applied accounting principles, distinct from the full Annual Report. Therefore, the correct classification is Audit Report / Information (AR).
2021-11-16 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 13-501F1' and is a management certification submitted to the Alberta Securities Commission. It includes detailed information about market values, trading periods, and participation fees for a reporting issuer, Marvel Biosciences Corp. The document is a certification by a company officer (CFO) confirming the accuracy and completeness of the information provided in the form. It does not contain financial statements or substantive financial data typical of annual or interim reports. Instead, it is a regulatory filing related to securities commission reporting requirements. According to the rules, documents that are primarily officer certifications or attestations, even if referencing financial data, should be classified as Regulatory Filings (RNS).
2021-11-16 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a news release announcing the appointment of a scientific advisory board for Marvel Biosciences Corp. It focuses on the company's strategic development and scientific guidance for its lead asset. There is no financial data, regulatory filing references, voting results, or report attachments. The content is an announcement about management/scientific advisory board changes rather than a formal management or board change announcement. However, given the nature of the announcement about the formation of a scientific advisory board, it best fits under Board/Management Information (MANG) as it relates to changes in the company's advisory and management structure.
2021-11-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing a new research program by Marvel Biosciences Corp. It discusses the initiation of a new drug development program and provides background on the company and its pipeline. There are no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed investor presentation. The document is a corporate announcement about a new program, typical of a press release or general regulatory announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. Given the nature of the content and the absence of financial or regulatory report data, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements and news releases that do not fit other categories.
2021-10-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.